The Most Promising New Cholesterol Drug Fails Huge Trial

A drug that crushed a dangerous cholesterol particle by up to 80 percent still failed to stop a single extra heart attack or stroke. That is the blunt result Novartis announced for pelacarsen, and it is forcing doctors to rethink a theory they have chased for over a decade.

Story Snapshot

Novartis said its drug pelacarsen missed the main goal of its huge phase three trial, called Lp(a)HORIZON, on September 4, 2026.
The drug lowered lipoprotein(a), a genetic risk marker known as Lp(a), but did not cut heart attacks, strokes, or cardiovascular deaths compared to a placebo.
The trial enrolled 8,325 patients who already had heart disease and high Lp(a) levels.
Novartis and partner Ionis Pharmaceuticals now face pressure on their cardiovascular drug pipelines and stock valuations.

What Novartis Actually Announced

Novartis said the pelacarsen phase three trial, called Lp(a)HORIZON, “did not meet its primary endpoint of reducing the risk of cardiovascular events.” That endpoint combined cardiovascular death, non-fatal heart attacks, non-fatal strokes, and emergency procedures to unclog arteries. Reuters summed it up simply: the drug lowered Lp(a) levels but failed to prevent major heart events. This was the first large outcomes trial ever run for an Lp(a)-lowering drug.

The trial was massive by cardiology standards. Ionis Pharmaceuticals announced in 2022 that enrollment had finished with 8,325 participants, all carrying elevated Lp(a) and already diagnosed with cardiovascular disease. Royalty Pharma, which holds a financial stake in the drug, confirmed the same negative topline update to investors on the day results came out. This was not a small or ambiguous study. It was built to give a clear answer, and it gave one.

Why Lowering The Marker Wasn’t Enough

Lp(a) is a cholesterol-carrying particle largely set by a person’s genes, not by diet or exercise. For years, doctors suspected it directly caused artery-clogging plaque. Pelacarsen worked exactly as designed. Earlier studies showed it cut Lp(a) by 35 percent to 80 percent depending on dose, far more than most drugs manage. That success is precisely why the outcome stings. Reducing the number on a lab report did not reduce the number of people who had heart attacks.

Cardiologists had flagged this exact risk before results came in. Expert reviews already warned that Lp(a) lowering had never been proven to change patient outcomes, even though earlier trials showed the drops in Lp(a) were large and long-lasting. A companion trial called ZEUS, testing a similar approach, ran into the same wall: strong biomarker reduction, no drop in cardiovascular events. Two failed trials in the same window make this look less like bad luck and more like a real scientific ceiling.

The Business Fallout For Novartis And Ionis

Novartis shares fell after the announcement, and Reuters reported the miss “increases pipeline pressure” on the Swiss drugmaker. Novartis had built financial expectations partly around pelacarsen becoming a blockbuster treatment for a large, underserved patient population. A negative trial does not just kill one drug; it forces investors to question every other early-stage cardiovascular bet in the company’s pipeline.

Ionis Pharmaceuticals, which developed the drug’s underlying technology, faces its own reckoning. Analysts noted this marks a second failed cardiovascular trial for the company, narrowing its story to a single approved product rather than a broad pipeline of promising candidates. Bloomberg called pelacarsen a drug “billed as a potential blockbuster” that instead delivered “a major setback for a new approach to prevent cardiovascular disease”. That framing matters because Wall Street had priced in success, not failure.

What This Means For Patients And Future Research

Doctors are not abandoning Lp(a) testing. Genetics still clearly link high Lp(a) to heart disease risk, and that biological link has not been erased by one trial. What has changed is the assumption that simply lowering the number with a drug automatically protects patients. That assumption now needs its own proof, drug by drug, rather than being taken for granted.

Other companies still have Lp(a)-lowering drugs in testing, and those trials will be watched far more closely now. Regulators and physicians will likely demand hard outcome data before approving any future drug in this class, no matter how impressive its effect on lab numbers looks. That is a reasonable, common-sense standard. Patients deserve treatments proven to prevent heart attacks, not just treatments that make a chart look better.

For now, the takeaway is straightforward. A well-designed, well-funded trial asked a direct question and got a direct answer. Pelacarsen lowered a genetic risk marker dramatically and still left patients just as likely to suffer a heart attack or stroke as those on a placebo. Science moved forward by ruling something out, even though it was not the answer anyone hoped for.